Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial
Journal of Cardiac Failure · 2026
DOI: 10.1016/j.cardfail.2026.02.045 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2026. Verfasst von Amrut V Ambardekar und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, University of Colorado, Aurora, CO, USA. Electronic address: amrut.ambardekar@cuanschutz.edu. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Cardiomyopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BridgeBio.
Abstract (Originalsprache)
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure, often leading to death, and it may be associated with low serum transthyretin (sTTR) levels. Acoramidis, a near-complete (≥90%) TTR stabilizer, increases sTTR levels and has demonstrated clinical efficacy in ATTR-CM. This report evaluates the association between the acoramidis-related early change from baseline in sTTR (ΔTTR) and cardiovascular-specific outcomes. METHODS: The 611 participants in the phase 3 (ATTRibute-CM) trial (NCT03860935; Efficacy and Safety of Acoramidis in Participants With Transthyretin Amyloid Cardiomyopathy) (acoramidis [409], placebo [202]) received oral acoramidis hydrochloride (800 mg) or placebo twice daily. Outcomes through month 30 included time to cardiovascular mortality (CVM) or first cardiovascular-related hospitalization (CVH), CVM alone, ΔTTR (day 28 until month 30), and the association between early ΔTTR (at day 28) and cardiovascular risk, including a mediation analysis. RESULTS: Acoramidis reduced the risk of CVM or first CVH vs placebo (33.3% vs 48.5%; hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.48-0.80; P < .001). A trend toward lower CVM with acoramidis was observed (14.9% vs 21.3%; HR 0.71; 95% CI 0.47, 1.05; P = .09). Cardiovascular benefits appeared to be mediated by acoramidis-induced ΔTTR (mean [standard error], 9.2 [0.25] mg/dL). Each 1- and 5-mg/dL increase in acoramidis-mediated early ΔTTR was associated with a 5.5% and 24.5% reduction in CVM and a 4.1% and 19.0% reduction in first CVH, respectively, over 30 months. CONCLUSIONS: In ATTRibute-CM trial, acoramidis led to early ΔTTR, which mediated, in part, reduced risks of CVM and first CVH over 30 months. This suggests that sTTR may serve as a clinically informative biomarker for ATTR-CM cardiovascular risk assessment following stabilizer initiation. TWEET: #Acoramidis led to an early increase in serum TTR (sTTR) that reduced risk of cardiovascular (CV) #mortality and first #CV-hospitalization over 30 months, suggesting that #sTTR may be a clinically informative biomarker after stabilizer initiation. @BridgeBioPharma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, University of Colorado, Aurora, CO, USA. Electronic address: amrut.ambardekar@cuanschutz.edu.
- Division of Cardiovascular Medicine, University of Chicago Medicine, Chicago, IL, USA.
- Cedars' Sinai Pacific Heart Institute, Santa Monica, CA, USA.
- Boston University, Boston, MA, USA.
- Division of Cardiology, University of British Columbia, Vancouver, Canada.
- Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Förderung
- BridgeBio
Zitieren
APA
Ambardekar, A. V., Sarswat, N., Wright, R., Berk, J., Davis, M. K., Garcia-Pavia, P., Gillmore, J. D., Grodin, J. L., Mitchell, J. D., Mooney, D., Nativi-Nicolau, J., Poulsen, S. H., Ruberg, F. L., Chen, C., Ji, A., Siddhanti, S., Tamby, J. F., Castaño, A., Katz, L., …, & Cheng, R. K. (2026). Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2026.02.045
Vancouver
Ambardekar AV, Sarswat N, Wright R, Berk J, Davis MK, Garcia-Pavia P, et al. Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2026.02.045
BibTeX
@article{Ambardekar2026,
author = {Ambardekar, Amrut V and Sarswat, Nitasha and Wright, Richard and Berk, John and Davis, Margot K and Garcia-Pavia, Pablo and Gillmore, Julian D and Grodin, Justin L and Mitchell, Joshua D and Mooney, Deirdre and Nativi-Nicolau, Jose and Poulsen, Steen H and Ruberg, Frederick L and Chen, Chris and Ji, Alan and Siddhanti, Suresh and Tamby, Jean-François and Castaño, Adam and Katz, Leonid and Sinha, Uma and Fox, Jonathan C and Maurer, Mathew S and Cheng, Richard K},
title = {Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial},
journal = {Journal of Cardiac Failure},
year = {2026},
doi = {10.1016/j.cardfail.2026.02.045}
}
EUVIMED